Year in Review: Navigating Cancer Leads Value-Based Cancer Care Innovation in 2019

by | Dec 30, 2019 | News

This has been a strong year for Navigating Cancer, as we remain the leading provider of patient relationship management software (PRM). We are pleased to continue our status as a frontrunner for oncology-focused technology development.

In 2019, we expanded the mobile experience of our platform for patients with remote monitoring tools for medication adherence, symptom reporting, and timely delivery of treatment-related information. We introduced Home Care Instructions, a powerful tool for the care team to close the loop immediately after triage-related phone calls, delivering related information directly to the patient via text message.

We also received recognition and validation that our PRM solution improves patient care with the announcement that McKesson Corporation chose us as a preferred vendor. As a result, our customer base also saw significant growth when Texas Oncology, a leader of The US Oncology Network, selected our PRM solution to help them meet their value-based care goals.

In addition to customer growth, we received an investment of $26 million in Series D growth equity funding from a diverse group of investors that included Merck Global Health Innovation Fund, TT Capital Partners, BrightEdge, the American Cancer Society’s newly formed philanthropic venture fund; LabCorp®; ORIX Growth Capital; and Rustic Canyon Partners.

Finally, we brought on Jeff Groh as Chief Financial Officer (CFO), as we continue to invest in top executive talent. Groh was previously serving as CFO at SCI Solutions and has extensive experience overseeing financial strategies and driving performance for major companies. We also announced the appointment of Dr. Ethan Basch, world-renowned patient-reported outcomes researcher, to our growing Medical Advisory Board.

As we look to 2020, we are excited to focus on developing robust solutions for value-based care, managing patients at a population level, and predictive and data-based capabilities to support the delivery of personalized medicine. We look forward to continuing our success in 2020 and helping lead the way for value-based cancer care technology. Thank you for our talented team and collaborative customers and partners for a great year!